<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751516</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC1225</org_study_id>
    <nct_id>NCT01751516</nct_id>
  </id_info>
  <brief_title>PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study</brief_title>
  <official_title>PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal&#xD;
      cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and&#xD;
      after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to determine the negative predictive value of PET/MRI&#xD;
      for determining pathological complete response from neoadjuvant chemoradiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">March 4, 2018</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology</measure>
    <time_frame>4-8 weeks post-chemoradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Rectal Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        UNC Hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage uT3n)&#xD;
             or uT1-3N+&#xD;
&#xD;
          -  Negative workup for distant disease&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Pre-treatment workup completed including:&#xD;
&#xD;
          -  history and physical&#xD;
&#xD;
          -  CT or MRI of the abdomen and pelvis&#xD;
&#xD;
          -  endoscopic tumor evaluation (biopsy, blood work to assess CEA and hematopoietic, renal&#xD;
             and liver function)&#xD;
&#xD;
          -  if female of child-bearing age, negative pregnancy test&#xD;
&#xD;
          -  Recommendation to undergo preoperative concurrent chemoradiation, as determined by the&#xD;
             treating physician&#xD;
&#xD;
          -  Informed consent reviewed and signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not deemed a candidate for preoperative chemoradiation for medical reasons, such as&#xD;
             uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac&#xD;
             disease&#xD;
&#xD;
          -  Hemoglobin ≤ 10.0 g/dL (transfusion allowed to achieve or maintain levels)&#xD;
&#xD;
          -  ANC ≤ 1,500/cubic mm³&#xD;
&#xD;
          -  Platelet count ≤ 100,000/mm³&#xD;
&#xD;
          -  ALT and AST ≥ 2.5 times upper level of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≥ 2.5 times ULN&#xD;
&#xD;
          -  Total bilirubin ≥ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          -  Creatinine ≥ 1.5 times ULN&#xD;
&#xD;
          -  Not deemed a candidate for concurrent preoperative chemoradiation for social reasons,&#xD;
             such as psychiatric illness&#xD;
&#xD;
          -  Not deemed a surgical candidate&#xD;
&#xD;
          -  Currently active second malignancy, except non-melanoma skin cancer, non-invasive&#xD;
             bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  Previous pelvic radiation therapy&#xD;
&#xD;
          -  History of severe reaction to gadolinium&#xD;
&#xD;
          -  Inability to tolerate MRI (e.g., inability to lie flat for &gt; 1 hour)&#xD;
&#xD;
          -  Presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear&#xD;
             implant or metal near eyes&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 35&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel E Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

